过敏护理市场－全球产业规模、份额、趋势、机会和预测：按类型、疗法、分销管道、地区和竞争格局划分，2021-2031年

全球过敏护理市场预计将从 2025 年的 238.7 亿美元大幅成长至 2031 年的 379.1 亿美元，复合年增长率为 8.01%。

该领域涵盖多种诊断方法、药物干预和免疫疗法，旨在检测和治疗由环境、药物和食物过敏原引起的免疫超敏反应。推动这一领域发展的关键因素包括：快速都市化导致过敏性疾病盛行率上升、污染加剧以及全球饮食结构变化。此外，大众对早期诊断和有效治疗重要性的认识不断提高，也推动了处方药和非处方治疗方法的需求。气喘与过敏基金会的数据凸显了这项负担，并预测到2025年，美国每年将有超过1亿人遭受各种过敏症的困扰。

儘管市场需求强劲，先进疗法的高成本是限制行业扩张的主要障碍。复杂的诊断测试和长期免疫疗法的巨额费用限制了相当一部分人群，特别是开发中国家的治疗机会。这种经济障碍有效地阻碍了综合过敏治疗方法的广泛应用。因此，治疗费用的可负担性仍然是一个重大挑战，可能会因为将无力承担这些昂贵医疗干预措施的潜在患者排除在外而抑制全球过敏治疗行业的预期增长。

市场驱动因素

免疫疗法的创新和新型生物製药的出现正在改变全球过敏症的治疗格局，将临床重点从暂时的症状管理转向长期的缓解疾病和脱敏治疗。近期出现的生物目标为重度IgE介导的食物过敏患者提供了一种突破性的治疗选择，这些患者先前只能依靠迴避策略。例如，基因泰克公司在2024年2月发布的新闻稿中提到，FDA核准了其产品Zoria上市，并指出在III期OUTMATCH试验中，67%的受试者能够单次服用600毫克花生蛋白而未出现中度至重度症状。这种提高过敏反应阈值的能力正在推动高价值处方笺的普及，并随着医疗机构将这些先进治疗方法纳入标准治疗通讯协定，扩大了该行业的商业性前景。

此外，快速的都市化和环境污染正在成为市场催化剂，而气候变迁则增加了过敏原暴露，延长了呼吸道过敏季节。全球暖化导致植物提早开花，花粉浓度升高，使得更多人需要持续治疗。根据哥伦比亚广播公司新闻网2024年4月报道，美国国家生物物候网路的数据显示，底特律等主要城市的春季比往年提早了23天。这种环境变化显着提升了大型製药公司的收益，同时也带来了需求的激增。赛诺菲在2024年报告称，其旗舰免疫疗法药物Dupixent第二季度的销售额增长了29.2%，达到33.03亿欧元。

市场挑战

高昂的专业诊断和长期免疫疗法费用仍然是全球过敏治疗市场成长的主要障碍。儘管过敏症的发生率持续上升，但综合治疗的高昂费用限制了全球相当一部分人口获得治疗的机会。这种经济障碍在开发中国家和未投保者人群中尤其严重，导致他们往往选择价格低廉的短期症状治疗，而不是必要的疾病管理。因此，该行业在将潜在患者群体转化为可靠的收入来源方面面临挑战，限制了在价格敏感型市场中治疗服务的扩充性。

这种经济差距的严重性从患者经济负担的统计中可见一斑。根据欧洲过敏与临床免疫学会的报告，预计到2025年，每位过敏性疾病患者的平均年度总费用将达到1,329.55欧元。如此沉重的经济负担阻碍了永续治疗方案的广泛应用。因此，这些经济限制直接限制了该行业最大限度地发挥其成长潜力，并深化在不同地区的市场渗透。

市场趋势

全球过敏治疗市场正经历舌下免疫疗法 (SLIT) 的重大转变，SLIT 已成为传统皮下注射疗法的替代方案。这一趋势的特征是标准化过敏原片剂的日益普及，患者可以在家中自行服用，有效避免了频繁就医和注射的麻烦。这种向非侵入性治疗的转变，透过提高患者依从性和便利性，扩大了呼吸道过敏治疗的潜在市场。近期财务表现也印证了此方法的商业性可行性。根据 ALK-Abello 于 2025 年 2 月发布的 2024 年年度报告，受欧洲市场销售成长和价格调整的推动，片剂销售额成长了 24%，达到 28.51 亿丹麦克朗。

与此同时，数位医疗和远距过敏咨询平台的兴起正在改变医疗服务模式，弥合了专科医生和患者之间的就医鸿沟。医疗服务提供者正日益利用整合的数位生态系统，透过电子咨询和远距分诊来简化患者就诊流程，并将离线资源优先用于复杂、高风险病例。这种数位化转型提高了临床效率，使过敏性疾病的管理无需患者亲自到场，并克服了基础设施的限制。临床数据也支持了这项转型的成功。根据发表在2024年4月《过敏前沿》（Frontiers in Allergy）杂誌上的一篇文章，2023年，来自基层医疗的电子咨询中有42.8%无需患者亲自到场即可成功解决。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球过敏护理市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（眼睛过敏、鼻炎、气喘、皮肤过敏、食物过敏、其他过敏）
  • 治疗方法（抗组织胺、免疫疗法）
  • 分销通路（医院、网路药局、零售药局、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美过敏护理市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲过敏护理市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区过敏护理市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲过敏护理市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲过敏护理市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球过敏护理市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• ALK-Abello A/S
• AbbVie Inc.
• Allergy Therapeutics PLC
• Bausch Health Companies Inc.
• Alembic Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd
• Nicox SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• LETI Pharma, SLU

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Allergy Care Market is projected to experience substantial growth, rising from a valuation of USD 23.87 Billion in 2025 to USD 37.91 Billion by 2031, reflecting a CAGR of 8.01%. This sector encompasses a wide array of diagnostics, pharmaceutical interventions, and immunotherapies aimed at detecting and treating immune hypersensitivities caused by environmental, pharmaceutical, or dietary allergens. Key factors propelling this expansion include the escalating prevalence of allergic conditions due to rapid urbanization, increasing pollution levels, and global changes in dietary patterns. Additionally, growing public awareness regarding the importance of early diagnosis and effective management is boosting the demand for both prescription and over-the-counter treatments. Data from the Asthma and Allergy Foundation of America highlights this burden, noting that in 2025, over 100 million people in the United States suffer from various allergies annually.

Despite strong market demand, high costs associated with advanced care present a major hurdle to industry expansion. The substantial expense of sophisticated diagnostic testing and long-duration immunotherapy regimens limits accessibility for a significant segment of the population, particularly within developing countries. This economic barrier effectively restricts the widespread adoption of comprehensive allergy solutions. Consequently, affordability remains a critical challenge that threatens to impede the anticipated growth trajectory of the global allergy care sector by excluding potential patients who cannot afford these premium medical interventions.

Market Driver

Innovations in immunotherapy and the emergence of novel biologics are transforming the global allergy care landscape by moving clinical focus from temporary symptom management to long-term disease modification and desensitization. The recent debut of targeted biological therapies has offered revolutionary alternatives for patients with severe IgE-mediated food allergies who previously depended entirely on avoidance strategies. For instance, a February 2024 press release from Genentech regarding the FDA approval of Xolair reported that 67% of Phase III OUtMATCH study participants could safely ingest a single 600 mg dose of peanut protein without experiencing moderate to severe symptoms. This capacity to elevate reaction thresholds is fueling the uptake of high-value prescriptions, broadening the sector's commercial prospects as healthcare providers adopt these advanced regimens into standard protocols.

Furthermore, rapid urbanization and environmental pollution act as substantial market catalysts, with climate change intensifying allergen exposure and prolonging respiratory allergy seasons. Rising global temperatures are triggering earlier plant blooming and higher pollen concentrations, necessitating continuous medical treatment for a broader demographic. A CBS News report from April 2024 noted that data from the USA National Phenology Network showed spring conditions arriving up to 23 days earlier than usual in major cities like Detroit. This environmental shift is driving significant revenue increases for leading pharmaceutical companies as demand escalates; Sanofi reported in 2024 that second-quarter sales of its blockbuster immunology drug Dupixent rose by 29.2% to reach €3,303 million.

Market Challenge

The prohibitive expense of specialized diagnostics and long-term immunotherapy remains a primary obstruction to the growth of the Global Allergy Care Market. While the incidence of hypersensitivities continues to climb, the steep costs attached to comprehensive care limit access for a vast portion of the global population. This financial hurdle is especially severe in developing countries and among uninsured groups, where individuals frequently opt for inexpensive, temporary symptomatic relief instead of necessary disease management. As a result, the industry faces difficulties in converting a high volume of potential patients into reliable revenue sources, which constrains the scalability of therapeutic offerings in price-sensitive markets.

The severity of this affordability gap is highlighted by statistical evidence regarding the financial burden on patients. According to reports from the European Academy of Allergy and Clinical Immunology, the average total cost per patient per year for allergic diseases was estimated at €1,329.55 in 2025. This substantial financial demand impedes the widespread uptake of sustained treatment plans. Consequently, these economic constraints directly hinder the industry's capacity to maximize its growth potential and achieve deeper market penetration across diverse global regions.

Market Trends

The Global Allergy Care Market is undergoing a significant transition toward Sublingual Immunotherapy (SLIT) as a favored alternative to conventional subcutaneous injections. This trend is defined by the growing uptake of standardized allergen tablets, which enable patients to self-administer disease-modifying therapies at home, effectively removing the logistical challenges associated with frequent clinic visits for shots. This move toward non-invasive care is broadening the addressable market for respiratory allergies by enhancing patient adherence and convenience. The commercial viability of this approach is evident in recent financial results; ALK-Abello's 2024 annual report, released in February 2025, indicated that tablet sales rose by 24% to DKK 2,851 million, fueled by increased volume and better pricing in European markets.

Simultaneously, the emergence of Digital Health and Tele-Allergy Platforms is transforming service delivery by closing the accessibility gap between specialists and patients. Providers are increasingly utilizing integrated digital ecosystems that leverage electronic consultations and remote triage to regulate patient flow, ensuring in-person resources are prioritized for complex, high-risk cases. This digital evolution enhances clinical efficiency and enables the management of allergic conditions without requiring physical attendance, thereby overcoming infrastructure limitations. The operational success of this shift is supported by clinical data; an April 2024 article in Frontiers in Allergy reported that 42.8% of electronic consultations originated from primary care in 2023 were resolved successfully without necessitating a face-to-face appointment.

Key Market Players

• ALK-Abello A/S
• AbbVie Inc.
• Allergy Therapeutics PLC
• Bausch Health Companies Inc.
• Alembic Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd
• Nicox SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• LETI Pharma, S.L.U

Report Scope

In this report, the Global Allergy Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Care Market, By Type

• Eye Allergy
• Rhinitis
• Asthma
• Skin Allergy
• Food Allergies
• Other Allergies

Allergy Care Market, By Treatment

• Anti-Allergy Drugs
• Immunotherapy

Allergy Care Market, By Distribution Channel

• Hospital
• Online Pharmacies
• Retail Pharmacies
• Others

Allergy Care Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Care Market.

Available Customizations:

Global Allergy Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Care Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, Other Allergies)
  • 5.2.2. By Treatment (Anti-Allergy Drugs, Immunotherapy)
  • 5.2.3. By Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Allergy Care Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Care Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Allergy Care Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Allergy Care Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Allergy Care Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy Care Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Allergy Care Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Allergy Care Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Allergy Care Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Allergy Care Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Allergy Care Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Allergy Care Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Allergy Care Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Allergy Care Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Allergy Care Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Allergy Care Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Allergy Care Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Allergy Care Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Allergy Care Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Allergy Care Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. South America Allergy Care Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Allergy Care Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Allergy Care Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Allergy Care Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Allergy Care Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ALK-Abello A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AbbVie Inc.
• 15.3. Allergy Therapeutics PLC
• 15.4. Bausch Health Companies Inc.
• 15.5. Alembic Pharmaceuticals Limited
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Nicox SA
• 15.8. GlaxoSmithKline PLC
• 15.9. Johnson & Johnson
• 15.10. LETI Pharma, S.L.U

16. Strategic Recommendations

17. About Us & Disclaimer